BOLD Company Profile and Key Details
NASDAQ : BOLD
Boundless Bio
$1.13
00
At Close 4:00 PMPrice Chart
Stock Price Today
Boundless Bio, Inc. (BOLD) stock remained unchanged at $1.13 a share on NASDAQ. The stock opened at $1.17, fluctuating between $1.13 to $1.17 during the session.
Stock Snapshot
1.13
Prev. Close
25.32M
Market Cap
1.13
Day Low
-0.43
P/E Ratio
-2.6
EPS (TTM)
N/A
Cash Flow per Share
1.17
Open
22.41M
Number of Shares
1.1707
Day High
73.54%
Free Float in %
N/A
Book Value
29.99K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Mar 25, 2026 | 1.17 | 1.17 | 1.13 | 1.13 | 30.01K |
| Mar 24, 2026 | 1.15 | 1.15 | 1.13 | 1.13 | 58.92K |
| Mar 23, 2026 | 1.18 | 1.19 | 1.15 | 1.15 | 70.58K |
| Mar 20, 2026 | 1.17 | 1.22 | 1.17 | 1.19 | 124.74K |
| Mar 19, 2026 | 1.15 | 1.17 | 1.15 | 1.15 | 21.37K |
| Mar 18, 2026 | 1.16 | 1.18 | 1.14 | 1.17 | 55.22K |
| Mar 17, 2026 | 1.13 | 1.16 | 1.13 | 1.15 | 20.81K |
| Mar 16, 2026 | 1.12 | 1.14 | 1.12 | 1.12 | 57.49K |
| Mar 13, 2026 | 1.13 | 1.14 | 1.10 | 1.11 | 42.88K |
| Mar 12, 2026 | 1.16 | 1.17 | 1.12 | 1.12 | 32.96K |
| Mar 11, 2026 | 1.15 | 1.17 | 1.13 | 1.16 | 48.25K |
| Mar 10, 2026 | 1.16 | 1.18 | 1.14 | 1.15 | 77.43K |
| Mar 09, 2026 | 1.15 | 1.15 | 1.12 | 1.14 | 76.47K |
| Mar 06, 2026 | 1.12 | 1.15 | 1.12 | 1.13 | 51.39K |
| Mar 03, 2026 | 1.16 | 1.16 | 1.13 | 1.13 | 68.02K |
| Mar 02, 2026 | 1.15 | 1.17 | 1.13 | 1.16 | 42.66K |
| Feb 27, 2026 | 1.15 | 1.18 | 1.14 | 1.16 | 90.25K |
| Feb 26, 2026 | 1.17 | 1.17 | 1.16 | 1.16 | 28.33K |
| Feb 25, 2026 | 1.17 | 1.20 | 1.15 | 1.17 | 88.84K |
| Feb 24, 2026 | 1.17 | 1.19 | 1.16 | 1.17 | 50.6K |
Contact Details
About Company
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Company Information
| Employees | 64 |
| Beta | -0.21 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
REGN
7.78+1.05%
Regeneron Pharmaceuticals, Inc.$749.47ARGX19.55+2.89%
argenx SE$697.05UTHR9.78+1.84%
United Therapeutics Corporation$541.60MDGL16.89+3.80%
Madrigal Pharmaceuticals, Inc.$461.93VRTX6.35+1.42%
Vertex Pharmaceuticals Incorporated$454.97KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83ALNY20.65+6.70%
Alnylam Pharmaceuticals, Inc.$328.70PRAX17.27+5.86%
Praxis Precision Medicines, Inc.$311.92KRYS7.86+3.18%
Krystal Biotech, Inc.$254.95SGEN-0.16-0.07%
Seagen Inc.$228.74Company Overview
The stock is currently mid-range between its 52-week high and low $0.96 and $1.78. With a market capitalization of about $25.32 million, Boundless Bio, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.21). Key stats such as the average daily volume over the past year has been around 112.72 thousand shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Boundless Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Zachary Hornby, the company employs approximately 64 people and listed since July 20, 2016. Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA.
Technical Performance
BOLD has shown mixed momentum, losing -0.81% over the past week and -10.22% over the past quarter, though year-to-date performance is up 2.5%. Short-term trend indicators are bullishly aligned (SMA20 1.78%, SMA50 -2.86%, SMA200 -3.82%). The stock’s 14-day RSI is 48.9 (neutral), while the ATR of 0.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -43.41% below its high and over 20.68% above its low. Average 10-day trading volume of 54.89 thousand shares is below the 3-month average of 111.69 thousand, indicating normal recent market interest.
Dividend & Fair Value
Boundless Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.24. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
Wall Street analysts project EPS growth of 35.77% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $4.00 to $4.00. The high target offers 253.98% upside. The low target suggests 253.98% downside. The mean target is $4.00. This offers 253.98% upside. Boundless Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by 16.98%. The prior quarter beat by -6.67%. Over the last six quarters, Apple has recorded several small beats. These include -1.28% in August 12, 2024.
Shareholding & Insider Activity
Boundless Bio, Inc. has 22.39 million shares outstanding. The public float is 16.46 million shares, elevated short interest at 0.72% of float. This equals 92.21 thousand shares. The short ratio is 1.1 days. Institutional investors hold 63.01% of the float. Insiders own 11.4%. SILVERSTEIN JONATHAN holds 4.80 million shares, ORBIMED ADVISORS LLC has 3.54 million shares and Flynn James E has 514.42 thousand shares.
Frequently Asked Questions
What is the current Boundless Bio, Inc. (BOLD) stock price?
Boundless Bio, Inc. (NASDAQ: BOLD) stock price is $1.13 in the last trading session. During the trading session, BOLD stock reached the peak price of $1.17 while $1.13 was the lowest point it dropped to. The percentage change in BOLD stock occurred in the recent session was 0% while the dollar amount for the price change in BOLD stock was $0.00.
BOLD's industry and sector of operation?
The NASDAQ listed BOLD is part of Biotechnology industry that operates in the broader Healthcare sector. Boundless Bio, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of BOLD?
No Data
How BOLD did perform over past 52-week?
BOLD's closing price is 17.59% higher than its 52-week low of $0.96 where as its distance from 52-week high of $1.78 is -36.52%.
How many employees does BOLD have?
Number of BOLD employees currently stands at 64.
Link for BOLD official website?
Official Website of BOLD is: https://boundlessbio.com
How do I contact BOLD?
BOLD could be contacted at phone 858 766 9912 and can also be accessed through its website. BOLD operates from 9880 Campus Point Drive, San Diego, CA 92121, United States.
How many shares of BOLD are traded daily?
BOLD stock volume for the day was 29.99K shares. The average number of BOLD shares traded daily for last 3 months was 112.72K.
What is the market cap of BOLD currently?
The market value of BOLD currently stands at $25.32M with its latest stock price at $1.13 and 22.41M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep